Graves Ophthalmopathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Graves ophthalmopathy (also known as Graves’ eye disease, Graves’ ophthalmopathy, Graves’ orbitopathy, TED) is an autoimmune inflammatory process that affects the periorbital and orbital tissue, closely associated with dysthyroidism. Thyroid eye disease is an autoimmune disorder. Usually caused by Graves’ disease, but it can also be associated with Hashimoto's thyroiditis.
·
It is estimated to be 16 per 100,000 women in
the general population and 2.9 per 100,000 men in the general population.
Thelansis’s “Graves Ophthalmopathy
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Graves
Ophthalmopathy treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Graves Ophthalmopathy across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Graves Ophthalmopathy Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment